NDAORALSOLUTION
Approved
Jun 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PARADIONE (paramethadione) is an oral solution small-molecule anticonvulsant approved in 1949 for seizure management. The drug is an oxazolidinedione class anticonvulsant used primarily for absence seizures and other seizure types. Mechanism of action involves modulation of neuronal excitability through effects on ion channels and neurotransmitter systems.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30), indicating a contracting commercial footprint and likely small team focused on managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PARADIONE offers limited career development opportunities given its LOE-approaching status and minimal linked job openings. Roles available are primarily defensive, focused on maintaining market position in a shrinking patient population rather than growth or innovation.
Brand Manager (Legacy)Field Sales (Specialty)
Worked on PARADIONE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.